Description

Telmisartan is a long-acting angiotensin II receptor blocker (ARB) used to study hypertension, cardiovascular protection, and renal health. It selectively blocks AT? receptors, producing vasodilation and reduced blood pressure. Telmisartan also partially activates PPAR??, enhancing insulin sensitivity and endothelial function

Yabang Hengbei Telmisartan Tablets are widely used in preclinical hypertension models, cardiovascular outcome research, and kidney injury studies.

Product Specifications

Mechanism of Action

Telmisartan blocks angiotensin II from binding to AT? receptors, reducing vasoconstriction and lowering blood pressure. It also partially activates PPAR??, which may improve insulin sensitivity and reduce tissue fibrosis

• Hypertension and cardiovascular modeling

• Renal protection and nephropathy studies

• PPAR??–mediated metabolic and fibrotic pathways

• Blood pressure pharmacodynamics

• Combination therapy assessments with diuretics or calcium channel blockers

Safety & Handling

• Use under standard lab protocols

• Wear PPE (gloves, protective eyewear) during handling

• Adverse effects in clinical models: dizziness, hypotension, hyperkalemia, renal impairment

• Pregnancy/Fetal risk: Significant fetal harm if administered during the second or third trimester

• Contraindications mimic clinical use: severe hepatic/renal impairment, pregnancy

Core Keywords

Telmisartan tablets 40mg, CAS 144701-48-4, ARB hypertension research drug, Yabang Hengbei telmisartan, PPAR?? telmisartan, laboratory hypertension models, telmisartan pharmacology, wholesale telmisartan tablets, telmisartan research supply

Research Use Disclaimer

This product is designated for laboratory and preclinical research only. It is not approved for clinical diagnosis, treatment, or human/veterinary use. Ensure all experimental protocols comply with regulatory and institutional guidelines.